Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals has launched Cefepime hydrochloride for injection, the generic equivalent of Maxipime marketed by Elan.
Subscribe to our email newsletter
APP’s cefepime is AP-rated, bar-coded and latex-free. Cefepime hydrochloride for injection is indicated in the treatment of the following infections: pneumonia, empiric therapy for febrile neutropenic patients, urinary tract infections (including pyelonephritis), skin and skin structure infections, and intra-abdominal Infections.
Tom Silberg, president of APP, said: “The launch of Cefepime further bolsters our leadership position as a provider of the broadest portfolio of generic anti-infective injectable products.”